Alnylam Pharmaceuticals, Inc. vs Walgreens Boots Alliance, Inc.: A Gross Profit Performance Breakdown

Alnylam vs. Walgreens: A Decade of Financial Evolution

__timestampAlnylam Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20145056100021569000000
Thursday, January 1, 20154109700026753000000
Friday, January 1, 20164715900029874000000
Sunday, January 1, 20177654500029162000000
Monday, January 1, 20187310600030792000000
Tuesday, January 1, 201919468800028159000000
Wednesday, January 1, 202041480100026077000000
Friday, January 1, 202170414300028067000000
Saturday, January 1, 202286860100028266000000
Sunday, January 1, 2023151788600027072000000
Monday, January 1, 2024192487300026524000000
Loading chart...

Unlocking the unknown

A Tale of Two Giants: Alnylam Pharmaceuticals vs. Walgreens Boots Alliance

In the ever-evolving landscape of the pharmaceutical and retail sectors, Alnylam Pharmaceuticals and Walgreens Boots Alliance stand as titans with distinct trajectories. From 2014 to 2023, Alnylam's gross profit surged by an impressive 2,900%, reflecting its innovative strides in RNA interference therapeutics. In contrast, Walgreens Boots Alliance, a stalwart in retail pharmacy, maintained a steady gross profit, peaking in 2018 with a 43% increase from 2014. This juxtaposition highlights the dynamic nature of the industry, where innovation and stability coexist. Notably, 2024 data for Alnylam is missing, leaving room for speculation on its future performance. As these companies navigate the complexities of their respective fields, their financial journeys offer valuable insights into the broader market trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025